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Editorial on the Research Topic
What’s New in Endocrinology?
As it approaches a decade since Frontiers in Endocrinology was launched, the Chief Editors have
commissioned a series of articles to reflect the continuing dynamic evolution of the science at
the Frontiers of Endocrinology. These articles highlight recent breakthroughs or advances, new
technologies, or challenges in the field of endocrinology. As with any dynamic field the frontiers
are ever changing and these articles exemplify some of the recent developments together with
some of the new questions and challenges for the future. The articles cover many different areas
of endocrinology including issues involved in some of the biggest health challenges facing today’s
society such as stress, obesity, reproduction, cancer, and aging.
The greatest challenge to health provision in virtually every country across the globe is obesity;
the scale of the epidemic threatens to outstrip resources in even the richest of societies (1).
The burden of morbidity arising from obesity and its sequelle of type 2 diabetes, cardiovascular
disease, and cancer present many challenges that are not restricted to those providing healthcare
but reaching across society. Big questions of how we feed ourselves and how we live our lives
need to be addressed (2); but some of the most fundamental questions center on how the body
regulates energy balance: essentially an endocrine question. Obesity is the direct result of a chronic
imbalance between energy intake and energy expenditure with the excess energy stored in adipose
tissue. Adipose tissue was traditionally considered a relatively inert tissue comprising cells that just
functioned as stores of excess energy in the form of lipids. This changed during the 1990’s when
it was discovered that adipocytes were an important source of key hormones such as leptin and
adiponectin with important roles in regulating both energy intake and expenditure (3). Interest in
adipose tissue was enhanced further around a decade ago when imaging techniques using labeled
glucose revealed that humans possess brown adipose tissue (BAT) (4). Whereas, white adipocytes
contain large stores of fats, in contrast brown adipocytes contain large numbers of mitochondia
in which uncoupling protein 1 (UCP1) enables energy to be dissipated as heat rather than being
stored. Until then it was considered that brown adipocytes were an important site of thermogenesis
and hence energy expenditure in rodents but were considered absent from humans. This raised
the potential of a new strategy to address human obesity by targeting BAT to enhance energy
expenditure. In a comprehensive article Carpentier et al. review the challenges that have been
encountered in the subsequent decade of research into BAT in humans. They address key questions
such as the true extent of BAT in humans; whether the original imaging techniques underestimated
the total mass of BAT and to what extent “beiging” of white adipocytes, with the induction of UCP1,
can occur in humans. These are critical questions that could establish whether beige and brown
adipocytes in humans could be an effective target to bring about changes in energy expenditure
that are of therapeutic benefit.
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In addition to the advances in our understanding of energy
expenditure there have been major progress in our knowledge
of the endocrine controls of energy intake via hormones that
control hunger and satiety and hence determine food intake (5).
Life within modern societies is increasingly stressful and whether
this impacts on the controls of appetite and satiety resulting in
over-eating is an interesting question. The effects of stress on the
gut-brain signaling pathways and the neuropeptides involved are
reviewed by Stengel and Taché.
The management of obesity remains a huge health challenge.
Numerous dietary and lifestyle changes have been proposed and
all have achieved modest weight loss that is invariably soon
regained. The pharmaceutical industry has invested considerably
in developing medications to treat the huge potential market
with a long trail of failures with many concerns regarding
adverse effects and long-term safety (2). While nutritionists,
physicians, and pharmacologists have floundered in the quest to
control the obesity epidemic; surgeons have developed a number
of bariatric procedures that result in effective and sustained
weight loss. One of the surprising observed effects of bariatric
surgery has been the remarkable correction of the metabolic
disturbances often resulting in complete remission of type 2
diabetes. That this effect is often apparent within days of surgery
and before any appreciable weight loss has challenged many
of our dogmas of the links between obesity and its associated
metabolic disturbances. Both Ma and Vella and Laferrère and
Pattou have reviewed the potential new insights into metabolic
endocrinology that these observations may provide. The clues
from the anatomical differences between the different surgical
procedures are reviewed by Ma and Vella. They describe how
such anatomical distinctions can provide insights into the various
hormonal pathways and in particular the interactions between
regions of the gut and the pancreas. They also touch on other
interesting, less well-appreciated effects, such as how the surgery
and endocrine changes can alter the perception of sweet-taste and
hence alter calorie intake. The most studied surgical intervention
is Roux-enY gastric bypass and Laferrère and Pattou review
these studies with an emphasis on what these studies have
revealed regarding the gut endocrine system. They highlight the
many new questions raised in relation to the role of satiety
hormones, incretins, and bile acids. Our concepts of bile acids
have been transformed from being regarded as just soaps that aid
in the uptake of dietary fats to being a previously unappreciated
complex endocrine system.
While the obesity epidemic has added to the focus on type
2 diabetes it has also become clear that there has been a 3%
annual increase in the incidence of type 1 diabetes and Jacobsen
et al. provide an overview of the development of strategies
to prevent this and avoid the need for lifelong treatment. In
order to prevent type I diabetes it is important to understand
the natural history of the development of the autoimmunity
that results in pancreatic beta cell destruction and the onset of
type 1 diabetes. The challenges of studying populations prior to
the disease onset and how this is being addressed around the
world are described. These studies have informed the various
trials for primary prevention in subjects at risk and secondary
prevention in those already exhibiting evidence of autoimmunity.
To date these studies have had limited success and new and future
strategies are discussed.
In a fine exposition of how studying one component can
help inform on how inter-connected the endocrine system has
become; Eiden and Jiang review how new observations of adrenal
chromaffin cells have contributed to our understanding of how
we coordinate response to stress. The adrenal medulla has
conventionally been considered the source of epinephrine to
coordinate the cardiovascular, neuronal, andmetabolic responses
to stress. In this overview they describe recent observations
of sympathetic nervous system regulation of chromaffin cell
function and its secretion of not just epinephrine but also a
rich cocktail of novel bioactive peptides. This new evidence is
synthesized into a broader understanding of how metabolic,
cardiovascular, and inflammatory responses are integrated. They
also highlight interesting new questions that have arisen from
this work; such as whether the sensory nervous system and
immune/inflammatory systems are looped-in together via the
adrenal medullary stress response and what are the broader
endocrine functions of themany bioactive peptides secreted from
the chromaffin cells.
Population control and reproductive health remain major
health issues globally. The important role of androgens both
in ovarian follicle selection to ensure mono-follicular ovulation
in women and in the normal cyclical secretion of estrodiol is
reviewed by Franks and Hardy. They focus on recent advances
regarding the role of androgens in the development of polycystic
ovary syndrome (PCOS), which remains the most common
endocrine disorder in women of reproductive age.
One of the recent advances in techniques for maintaining
fertility in women has been ovarian tissue cryopreservation
(OTC) and transplantation. Originally developed to assist
prepubertal girls and young women faced with reductions in
the ovarian reserve due to pathologies, such as malignancies, or
due to aggressive therapies that damage the ovary, Kristensen
and Andersen discuss the many issues and challenges with
extending this technique to more broader applications. Using
this technique to restore fertility to women with anovulatory
PCOS is discussed. The many issues surrounding the more
controversial application of the technique to enable healthy
women to postpone childbearing into their more advanced years
is also addressed.
During pregnancy a woman’s endocrine system kicks into
overdrive with most hormones adapting to enable the mother
to meet the additional metabolic demands and to provide an
optimal environment in which the fetus can develop. Among all
of these hormonal changes vitamin D plays an under-appreciated
role both in ensuring adequate calcium availability for fetal
bone development and in enhancing maternal tolerance to the
presence of paternal and fetal alloantigens. Recent advances in
our understanding of the part played by vitamin D-binding
protein (VDBP) in facilitating these roles is reviewed by Karras
et al.. The ongoing questions regarding the role of VDBP in
important clinical issues such as preeclampsia, preterm birth, and
gestational diabetes are discussed.
Neuropeptide G protein-coupled receptors (GPCRs) are over-
expressed in many different cancers; not just the relatively rare
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neuroendocrine tumors but also in some common cancers such
as small cell lung cancers. The potential targeting of specific
GPCRs for the development of novel cancer therapies is reviewed
by Moody et al.. The development of agents that target receptors
for bombesin, neurotensin, vasoactive intestinal peptide, and
somatostatin are described in relation to the detection and
treatment of both endocrine and non-endocrine cancers.
Recent advances in the genetics, biochemical characterization,
and imaging of pheochromocytomas (PCCs) and paragangliomas
(PGLs) are reviewed by Alrezk et al.. These are challenging
cancers to treat and although most can be cured by surgery on
rare occasions they metastasize and for these there are currently
no approved treatments. The potential of systemic therapies, that
have largely been developed to treat other cancers, is reviewed
by Jimenez. Different strategies that have been designed to target
each of the accepted “hallmarks” are discussed in relation to their
application to treating PCCs and PGLs. These include different
strategies to inhibit angiogenesis, cell proliferation, invasion, and
metastasis, to enhance the induction of cell death and the recently
developed immunotherapies.
As more and more people survive into advanced ages the
problems of the elderly become an increasing burden on clinical
services. The prevalence of thyroid nodules in people over the
age of 60 years is extremely high (50–70%) and although most
of these are benign (85–95%) it is important to distinguish
the few that can become malignant and require surgery. The
current status of molecular markers for the differential diagnosis
of malignant, vs. benign, thyroid nodules is reviewed by Sahli
et al.. The limitations of current genetic markers, their cost-
effectiveness and the next generation of tests currently being
evaluated are discussed.
Another common ailment associated with aging is osteopenia,
which leads to the high prevalence of fractures seen in the elderly
population. The challenges of identifying individuals at risk of
fractures and the uses and limitations of current therapies for
osteopenia are discussed by Ramchand and Seeman. The relative
merits of antiresorptive and anabolic therapies are discussed as
are the alternative strategies of combining these therapies or
using them sequentially.
The increasing speed of technological advances provides
endocrinologists with ever more powerful tools for investigation,
diagnosis and treatment. As the pressures of modern lifestyles
involve major changes in how we live and eat and demographics
markedly increase the elderly population the challenges
endocrinologists face in the clinic are constantly evolving. This
collection of articles illustrates the variety of these challenges
across the different specialties within endocrinology and the
dynamic nature of modern endocrinology.
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